|Table of Contents|

Efficacy analysis of neoadjuvant chemotherapy alone in the treatment of advanced low rectal cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 18
Page:
3411-3415
Research Field:
Publishing date:

Info

Title:
Efficacy analysis of neoadjuvant chemotherapy alone in the treatment of advanced low rectal cancer
Author(s):
WANG Shaoyi; BAI Qiangshan; CHEN An
Department of General Surgery,the Second Affiliated Hospital of Airforce Military Medical University（Tangdu Hospital）,Shaanxi Xi'an 710038,China.
Keywords:
neoadjuvant chemotherapy; rectal cancer; adjuvant chemotherapy; LARS
PACS:
R735.3+7
DOI:
10.3969/j.issn.1672-4992.2023.18.014
Abstract:
Objective:To evaluate the efficacy of neoadjuvant chemotherapy alone for advanced low rectal cancer,and to explore the effect of neoadjuvant chemotherapy on the incidence of LARS in rectal cancer patients after surgery.Methods：Retrospective analysis of the clinical data of 60 patients with rectal cancer who received laparoscopic radical surgery during the clinical progression period from January 1,2012 to January 1,2021 in general surgery of our hospital.Patients were divided into neoadjuvant chemotherapy (NACT) and adjuvant chemotherapy (ACT) groups according to whether they received neoadjuvant chemotherapy.The general clinical data,side effects of chemotherapy,operative complications,operative duration,operative bleeding,length of stay,hospitalization expenses,negative rate of tumor markers,remission rate of tumor,reduction rate of tumor stage,grade of tumor reaction after chemotherapy,disease-free survival curve and overall survival curve were analyzed and compared retrospectively,LARS scores at 1,3,6,12 months after surgery.Results：There was no significant difference between the NACT group and the ACT group in operative complications,postoperative exhaust time and length of hospital stay (P＞0.05).NACT group was significantly superior to ACT group in terms of adverse reaction of chemotherapy,negative conversion rate of CEA and CA19-9 after operation,operation time,blood loss and hospital cost (P＜0.05).On the DFS and OS survival curves,as time went on,the NACT survival curve decreased less than the ACT group,and the DFS survival curve had significant difference (P＜0.05),but the OS survival curve had no significant difference (P＞0.05).There was no significant difference between the NACT group and the ACT group in LARS scores at different stages after surgery (P＞0.05),and the decrease in LARS scores was the most significant in both groups at 1 year after surgery (P＞0.05).Conclusion：Neoadjuvant chemotherapy alone also significantly improved the outcome of patients with rectal cancer,without affecting the incidence and severity of LARS after surgery.

References:

［1］SUNG H,FERLAY J,SIEGEL RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA:A Cancer Journal for Clinicians,2021,71(3):209-249.
［2］RODEJ C,LIERSCH T,BECKER H,et al.Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer:initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial［J］.Lancet Oncol,2012,13(7):679-687.
［3］TRENTI L,GALVEZ A,BIONDO S,et al.Quality of life and anterior resection syndrome after surgery for mid to low rectal cancer:A cross-sectional study［J］.Eur J Surg Oncol,2018,44(7):1031-1039.
［4］STURIALE A,MARTELLUCCI J,ZURLI L,et al.Long-term functional follow-up after anterior rectal resection for cancer［J］.Int J Colorectal Dis,2017,32(1):83-88.
［5］OKUYAMA T,SAMESHIMA S,TAKESHITA E,et al.Therapeutic effects of oxaliplatin-based neoadjuvant chemotherapy and chemoradiotherapy in patients with locally advanced rectal cancer:a single-center,retrospective cohort study［J］.World J Surg Oncol,2018,16(1):105.
［6］曹兰玉,魏力,王春梅.直肠癌前切除综合征评分量表的汉化及信效度评价［J］.中国实用护理杂志,2013,29(27):69-72. CAO YL,WEI L,WANG CM.Reliability and validity of the Chinese version of the rectal anterior resection syndrome scale［J］.Chinese Journal of Practical Nursing,2013,29(27):69-72.
［7］王傲,张敬,黄维,等.结直肠癌重度低位前切除综合征危险因素的Meta分析［J］.四川医学,2022,43(8):793-798. WANG A,ZHANG J,HUANG W,et al.Meta-analysis of risk factors for severe low anterior resection syndrome in colorectal cancer［J］.Sichuan Medicine，2022,43(8):793-798.
［8］RIZZO G,PAFUNDI DP,SIONNE F,et al.Preoperative chemoradiotherapy affects postoperative outcomes and functional results in patients treated with transanal endoscopic microsurgery for rectal neoplasms［J］.Tech Coloproctol,2021,25(3):319-331.
［9］王英斌,徐兴伟,邵泉,等.新辅助化疗在局部进展期直肠癌中的应用效果［J］.中华普通外科杂志,2020,35(10):768-772. WANG YB,XU XW,SHAO Q,et al.Effect of neoadjuvant chemotherapy in locally advanced rectal cancer［J］.Chinese Journal of General Surgery,2020,35(10):768-772.
［10］韩鹏,陈晨,崔滨滨.局部进展期直肠癌单纯应用新辅助化疗研究进展［J］.中国实用外科杂志,2020,40(10):1214-1218. HAN P,CHEN C,CUI BB.Advances in neoadjuvant chemotherapy alone for locally advanced rectal cancer［J］.Chinese Journal of Practical Surgery,2020,40(10):1214-1218.
［11］高树全,张超,张迎春,等.中低位局部进展期直肠癌术前采用新辅助放化疗和全程新辅助治疗的近期疗效与安全性［J］.临床和实验医学杂志,2021,20(5):504-507. GAO SQ,ZHANG C,ZHANG YC,et al.The short-term efficacy and safety of preoperative neoadjuvant chemoradiotherapy and whole-course neoadjuvant therapy for locally advanced rectal cancer［J］.Journal of Clinical and Experimental Medicine,2021,20(5):504-507.
［12］JALIL O,L CLAYDON,T ARULAMPALAM.Review of neoadjuvant chemotherapy alone in locally advanced rectal cancer［J］.J Gastrointest Cancer,2015,46(3):219-236.
［13］黎华丽,郑勇斌,程煌荣,等.肿瘤标志物和Ki67在结直肠癌中的表达及预后因素分析［J］.腹部外科,2021,34(2):110-114. LI HL,ZHENG YB,CHENG HR,et al.Expression of tumor markers and Ki67 in colorectal carcinoma and analysis of prognostic factors［J］.Abdominal Surgery,2021,34(2):110-114.
［14］惠瞳,陈颖慧,王黄震.术前新辅助化疗在超低位直肠癌内括约肌切除术患者中的应用效果［J］.癌症进展,2022,20(17):1794-1797. HUI T,CHEN YH,WANG HZ.Preoperative neoadjuvant chemotherapy in patients with ultra-low rectal cancer after internal sphincterotomy［J］.Cancer Progression,2022,20(17):1794-1797.
［15］WEISER MR.Progress in the PROSPECT trial:precision treatment for rectal cancer［J］.Bull Am Coll Surg,2015,100(4):51-52.
［16］严虹霞,卢艳军,李建英,等.新辅助化疗与新辅助放化疗联合直肠癌手术的治疗效果比较［J］.中国医院药学杂志,2019,39(12):1287-1292. YAN HX,LU YJ,LI JY,et al.Comparison of neoadjuvant chemotherapy and neoadjuvant chemoradiotherapy combined with rectal cancer surgery［J］.Chinese Journal of Hospital Pharmacy,2019,39(12):1287-1292.
［17］刘凡,郭鹏,申占龙,等.低位前切除综合征相关危险因素分析［J］.中华胃肠外科杂志,2017,20(3):289-294. LIU F,GUO P,SHEN ZL,et al.Analysis of risk factors associated with low anterior resection syndrome［J］.Chinese Journal of Gastrointestinal Surgery,2017,20(3):289-294.
［18］徐玲,丁曙晴,丁义江.直肠癌前切除术后生活质量及前切除综合征相关因素分析［J］.临床外科杂志,2019,27(12):1049-1052. XU L,DING SQ,DING YJ.Quality of life and related factors of anterior resection syndrome after anterior resection of rectal cancer［J］.Journal of Clinical Surgery,2019,27(12):1049-1052.
［19］MERKEL S.Prognostic subdivision of ypT3 rectal tumours according to extension beyond the muscularis propria［J］.Br J Surg,2014，101(5):566-572.
［20］田衍,罗华友.老年直肠癌根治术后局部复发的危险因素分析［J］.中国普通外科杂志,2014,23(4):533-536. TIAN Y,LUO HY.Risk factors for local recurrence after radical resection of rectal cancer in the elderly［J］.Chinese Journal of General Surgery,2014,23(4):533-536.

Memo

Memo:
-
Last Update: 1900-01-01